NeoTherapeutics Loss
IRVINE — NeoTherapeutics Inc., which develops drugs to treat neurodegenerative diseases, reported a net loss of $1 million, or 31 cents a share, for 1996, compared with a net loss of $895,378, or 36 cents a share, for 1995. The company said the higher loss was principally due to increased expenditures for research and development made possible by new equity capital from the September 1996 public offering of common stock. No revenue was recorded for 1996, while $125,431 from grants was posted for 1995.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
